Kura Oncology (NASDAQ:KURA) Insider Sells 8,442 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Bair sold 8,442 shares of the business’s stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $10.50, for a total transaction of $88,641.00. Following the sale, the insider owned 187,002 shares in the company, valued at $1,963,521. This represents a 4.32% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Teresa Brophy Bair also recently made the following trade(s):

• On Wednesday, August 19th, Teresa Bair sold 31,487 shares of Kura Oncology stock. The stock was sold at an average price of $12.63, for a total transaction of $397,680.81.

Kura Oncology Trading Up 1.9%

NASDAQ KURA traded up $0.20 on Tuesday, hitting $10.81. 1,890,260 shares of the stock were exchanged, compared to its average volume of 1,673,937. The company’s 50-day moving average price is $11.22 and its two-hundred day moving average price is $10.15. The company has a debt-to-equity ratio of 0.12, a current ratio of 4.73 and a quick ratio of 4.71. Kura Oncology, Inc. has a 52-week low of $7.36 and a 52-week high of $13.90. The company has a market capitalization of $961.66 million, a price-to-earnings ratio of -3.21 and a beta of 0.44.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The business had revenue of $20.87 million during the quarter, compared to analysts’ expectations of $20.16 million. Research analysts predict that Kura Oncology, Inc. will post -3.25 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on KURA shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Citizens Jmp reiterated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a research report on Monday, August 24th. CLSA set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, June 4th. Wells Fargo & Company set a $24.00 price target on shares of Kura Oncology in a research note on Thursday, June 4th. Finally, Wedbush lifted their price objective on Kura Oncology from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $25.40.

Institutional Trading of Kura Oncology

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in shares of Kura Oncology in the 2nd quarter valued at $115,286,000. Armistice Capital LLC raised its holdings in Kura Oncology by 5.7% during the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock valued at $51,285,000 after buying an additional 264,000 shares in the last quarter. Bank of America Corp DE bought a new position in Kura Oncology during the second quarter valued at about $12,735,000. Dimensional Fund Advisors LP lifted its position in shares of Kura Oncology by 32.3% in the first quarter. Dimensional Fund Advisors LP now owns 1,425,945 shares of the company’s stock worth $11,591,000 after buying an additional 348,127 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Kura Oncology in the second quarter worth about $10,927,000.

Kura Oncology News Summary

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KO-7246 regenerated functional pancreatic beta-cell mass and improved glycemic control in Type 1 and Type 2 diabetes models. Benefits persisted for at least one month after treatment stopped in a Type 1 diabetes model, suggesting potential disease-modifying activity. KO-7246 EASD announcement
• Positive Sentiment: The candidate increased beta-cell mass, endogenous insulin and C-peptide levels, and showed enhanced activity when combined with semaglutide. Results in human pancreatic islets also indicated selective beta-cell proliferation and improved glucose-responsive insulin secretion, strengthening the potential commercial value of Kura’s menin-inhibitor platform. KO-7246 preclinical data
• Neutral Sentiment: KO-7246 remains preclinical. Caspian plans IND-enabling work and a future Phase 1 study, with management scheduled to discuss the program on October 13. Any valuation benefit for KURA therefore depends on future clinical progress and the terms of Kura’s relationship with Caspian. Caspian and Kura KO-7246 report
• Negative Sentiment: Several Kura executives and insiders sold shares on September 28–29, including Mollie Leoni, Brian Powl, Kathleen Ford, Thomas Doyle and Teresa Bair. The transactions totaled approximately 97,000 shares and more than $1 million, signaling near-term insider selling pressure even though the sellers retained substantial holdings. Kura insider ownership filing
• Negative Sentiment: The diabetes opportunity carries substantial execution risk, including potential clinical or regulatory setbacks, unexpected safety findings and the need for additional financing before human trials can begin.

Kura Oncology Company Profile

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.